This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
PARD3B Polyclonal Antibody
catalog :
PA5-37974
quantity :
100 ug
price :
US 464.00
clonality :
polyclonal
host :
domestic goat
conjugate :
nonconjugated
reactivity :
mouse
application :
western blot
product information
Product Type :
Antibody
Product Name :
PARD3B Polyclonal Antibody
Catalog # :
PA5-37974
Quantity :
100 ug
Price :
US 464.00
Clonality :
Polyclonal
Purity :
Ammonium sulfate precipitation
Host :
Goat
Reactivity :
Mouse
Applications :
Western Blot: 0.3-1 ug/mL
Species :
Mouse
Isotype :
IgG
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Immunogen :
Peptide with sequence C-RNQDPRQKNP, from the C-Terminus of mouse Pard3b (aa 1189-1199).
Format :
Liquid
Applications w/Dilutions :
Western Blot: 0.3-1 ug/mL
Aliases :
1810008K04Rik; 2010002N16Rik; 2810455B10Rik; Als2cr19; amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 19; amyotrophic lateral sclerosis 2 chromosomal region candidate gene 19 protein; Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 19 protein homolog; C. elegans; DN-276O13.2; par-3 family cell polarity regulator beta; par-3 partitioning defective 3 homolog B; PAR3B; PAR3beta; PAR3-beta; PAR3L; PAR3-L protein; Pard3b; Partitioning defective 3 homolog B; partitioning defective 3-like protein; partitioning-defective 3-beta; RP23-20G7.1
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments